Trending NewsTrending NewsNASDAQ:BBNX Beta Bionics (BBNX) Stock Price, News & Analysis $19.42 -1.10 (-5.36%) As of 01:11 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Beta Bionics Stock (NASDAQ:BBNX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Beta Bionics alerts:Sign Up Key Stats Today's Range$19.29▼$20.7350-Day Range$12.83▼$22.8152-Week Range$8.80▼$32.71Volume244,508 shsAverage Volume1.19 million shsMarket Capitalization$873.71 millionP/E RatioN/ADividend YieldN/APrice Target$22.91Consensus RatingModerate Buy Company Overview Beta Bionics, Inc. is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input. The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes. The system combines an insulin pump, dosing-control software and a compatible continuous glucose monitor, and is designed to reduce the need for users to calculate insulin doses manually. Beta Bionics also develops related technologies intended to support automated diabetes care. The company was founded by Ed Damiano, an engineering professor and researcher whose work on automated insulin delivery helped lead to the development of the iLet system. Beta Bionics is based in the United States and initially serves the U.S. diabetes-care market through its commercialized iLet product.AI Generated. May Contain Errors. Read More Beta Bionics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreBBNX MarketRank™: Beta Bionics scored higher than 35% of companies evaluated by MarketBeat, and ranked 767th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingBeta Bionics has received a consensus rating of Moderate Buy. The company's average rating score is 2.54, and is based on no strong buy ratings, 8 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialBeta Bionics has a consensus price target of $22.91, representing about 18.0% upside from its current price of $19.42.Amount of Analyst CoverageBeta Bionics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Beta Bionics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Beta Bionics are expected to decrease in the coming year, from ($2.06) to ($2.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Beta Bionics is -11.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Beta Bionics is -11.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeta Bionics has a P/B Ratio of 2.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.92% of the float of Beta Bionics has been sold short.Short Interest Ratio / Days to CoverBeta Bionics has a short interest ratio ("days to cover") of 9.91.Change versus previous monthShort interest in Beta Bionics has recently increased by 12.95%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBeta Bionics does not currently pay a dividend.Dividend GrowthBeta Bionics does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.27 News SentimentBeta Bionics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 50 news articles for Beta Bionics this week, compared to 9 articles on an average week.Search InterestOnly 1 people have searched for BBNX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Beta Bionics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,983,398.00 in company stock.Percentage Held by Insiders5.30% of the stock of Beta Bionics is held by insiders.Percentage Held by InstitutionsBeta Bionics has minimal institutional ownership at this time.Read more about Beta Bionics' insider trading history. Receive BBNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beta Bionics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BBNX Stock News HeadlinesBeta Bionics (NASDAQ: BBNX) Faces Securities Fraud Class Action Amid iLet FDA Compliance -- HBSS31 minutes ago | prnewswire.comSueWallSt Reminds Beta Bionics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 3, 2026 - BBNX2 hours ago | globenewswire.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.September 29 at 1:00 AM | Stansberry Research (Ad)BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit2 hours ago | globenewswire.comBeta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026September 29 at 8:00 AM | globenewswire.comInsider Selling: Beta Bionics (NASDAQ:BBNX) Director Sells 6,430 SharesSeptember 24, 2026 | insidertrades.comMike Mensinger Sells 2,650 Shares of Beta Bionics (NASDAQ:BBNX) StockSeptember 18, 2026 | insidertrades.comBeta Bionics (NASDAQ:BBNX) Insider Sells 4,221 Shares of StockSeptember 4, 2026 | insidertrades.comSee More Headlines BBNX Stock Analysis - Frequently Asked Questions How have BBNX shares performed this year? Beta Bionics' stock was trading at $30.47 at the start of the year. Since then, BBNX stock has decreased by 36.3% and is now trading at $19.42. How were Beta Bionics' earnings last quarter? Beta Bionics, Inc. (NASDAQ:BBNX) released its quarterly earnings results on Wednesday, July, 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. The firm earned $32.01 million during the quarter. Beta Bionics had a negative net margin of 61.31% and a negative trailing twelve-month return on equity of 26.30%. Read the conference call transcript. When did Beta Bionics IPO? Beta Bionics (BBNX) raised $198 million in an initial public offering on Thursday, January 30th 2025. The company issued 12,000,000 shares at $16.00-$17.00 per share. How do I buy shares of Beta Bionics? Shares of BBNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings7/29/2026Today9/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 BBNX's financial health is in the Green zone, according to TradeSmith. BBNX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:BBNX Previous SymbolNASDAQ:BBNX CIK1674632 Webwww.betabionics.com Phone(949) 427-7785FaxN/AEmployees423Year Founded2015Price Target and Rating Average Price Target for Beta Bionics$22.91 High Price Target$32.00 Low Price Target$16.00 Potential Upside/Downside+17.8%Consensus RatingModerate Buy Rating Score (0-4)2.54 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$73.20 million Net Margins-61.31% Pretax Margin-61.31% Return on Equity-26.30% Return on Assets-23.25% Debt Debt-to-Equity RatioN/A Current Ratio8.88 Quick Ratio7.96 Sales & Book Value Annual Sales$100.25 million Price / Sales8.72 Cash FlowN/A Price / Cash FlowN/A Book Value$6.53 per share Price / Book2.98Miscellaneous Outstanding Shares44,990,000Free Float42,606,000Market Cap$874.65 million OptionableN/A Beta3.37 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:BBNX) was last updated on 9/29/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beta Bionics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beta Bionics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
